Clinical Trials Browser

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT02959398 2017-11-24

ETOLE

Phase NA Unknown

2,000 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00419510 2016-08-17

Genetic Counseling in African American Women

Phase NA Completed

204 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01346761 2016-04-14

REACH

Phase NA Completed

1,012 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms, Genetic Predisposition to Disease

NCT00413491 2014-05-20

MR BRCA

Phase 4 Unknown

300 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Phase NA Completed

150 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Olaparib In Metastatic Breast Cancer

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

ICEBERG 1

Methods in Education for Breast Cancer Genetics

REVIVAL

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

ETOLE

Genetic Counseling in African American Women

REACH

MR BRCA

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing